Disclosure Of Interests In Other Entities [Text Block]

OSE Immunotherapeutics - Filing #880997

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	As at 2019-12-31
Disclosure of interests in other entities [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of interests in subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [abstract]
Disclosure of subsidiaries [line items]
Current assets	44 206 EUR	—	—	—	—	—	—	39 832 EUR	—	—	—	—	—	—	—
Non-current assets	57 670 EUR	—	—	—	—	—	—	57 141 EUR	—	—	—	—	—	—	—
Current liabilities	16 761 EUR	—	—	—	—	—	—	14 128 EUR	—	—	—	—	—	—	—
Non-current liabilities	37 224 EUR	—	—	—	—	—	—	21 481 EUR	—	—	—	—	—	—	—
Revenue	—	—	—	—	—	—	26 306 EUR	—	—	10 432 EUR	—	—	—	—	—
Profit (loss)	—	16 850 EUR	—	—	—	—	16 850 EUR	—	—	16 555 EUR	—	—	—	16 555 EUR	—
Comprehensive income	—	16 825 EUR	0 EUR	0 EUR	0 EUR	55,000 EUR	16 879 EUR	—	0 EUR	16 561 EUR	4,000 EUR	0 EUR	0 EUR	16 558 EUR	—
Disclosure of interests in associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [abstract]
Disclosure of associates [line items]
Other comprehensive income	—	—	—	—	—	—	29,000 EUR	—	—	7,000 EUR	—	—	—	—	—
Disclosure of interests in joint arrangements [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [abstract]
Disclosure of joint ventures [line items]
Cash and cash equivalents	33 579 EUR	—	—	—	—	—	—	29 368 EUR	—	—	—	—	—	—	25 842 EUR
Tax expense (income)	—	—	—	—	—	—	364,000 EUR	—	—	2 692 EUR	—	—	—	—	—